- Home
- MUR vs MIRM Comparison
MUR vs MIRM Comparison
Compare MUR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | MIRM |
|---|---|---|
| Founded | 1950 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.4B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MUR | MIRM |
|---|---|---|
| Price | $35.92 | $92.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $30.62 | ★ $114.67 |
| AVG Volume (30 Days) | ★ 2.3M | 704.8K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $2,718,823,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | $14.67 | $21.75 |
| P/E Ratio | $51.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.95 | $36.88 |
| 52 Week High | $36.90 | $109.28 |
Technical Indicators
Market Signals| Indicator | MUR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 48.00 |
| Support Level | $29.81 | $72.17 |
| Resistance Level | N/A | $107.51 |
| Average True Range (ATR) | 1.50 | 4.04 |
| MACD | 0.23 | -0.56 |
| Stochastic Oscillator | 86.81 | 30.40 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.